sailife.comCrawled Nov 10, 2026
Sai Life Sciences leverages proprietary technology platforms to accelerate drug product development, helping pharma clients reduce timelines and improve outcomes from discovery to GMP.
Explore Sai Life Sciences brochures to know more about discovery and manufacturing capabilities
Dhruva is Sai Life Sciences' proprietary intelligent process flow and risk evaluation platform, designed to streamline decision-making and enhance operational efficiency in pharma R&D.
Sai Life Sciences hires for roles in drug discovery, chemistry, and life sciences innovation across its global team.
Sai Life Sciences Boston recruits for discovery biology roles supporting biotech and drug discovery programs.
Sai Life Sciences posts job openings in India for positions in complex chemistry and drug development.
A pure-play CRDMO with no competing product business — full-service from discovery to manufacturing for 280+ pharma and biotech innovators.
Sai Cares drives CSR initiatives in education, healthcare, environment, and livelihoods to empower communities.
Sai Life Sciences uses a health, safety, and environment framework to support safe pharmaceutical operations through governance, training, and environmental responsibility.
Investor relations information including financial reports, governance updates, and shareholder resources.
Integrated CRDMO advancing drug programs from discovery to commercial manufacturing with speed, science, and scale.
Sai Life Sciences’ stock price jumps 10% to ₹1,775, marking its all-time high on the National Stock Exchange (NSE) following strong second-quarter financial results. The company’s earnings performance drives investor confidence, propelling its market valuation. The surge reflects positive sentiment around its Q2 performance.
Nov 2026business-standard.comNews article
Nippon India Mutual Fund, BlackRock, and Societe Generale lead a consortium acquiring a 10% stake in **Sai Life Sciences** for **₹1,505 crore** through open market transactions. The deal consolidates institutional interest in the pharmaceutical company, following a structured investment approach. The transaction reflects growing confidence in Sai Life Sciences’ market position and operational scale.
Jun 2025RediffNews article
Sai Life Sciences lists its shares at a **20% premium on BSE** and **above 18% on NSE**. Investment experts recommend a **HOLD strategy** for the newly listed pharma stock, citing long-term growth potential. The company’s listing reflects strong market demand amid optimism for its future performance.
Dec 2024https://www.goodreturns.in/News article
Sai Life Sciences lists its shares at a 20% premium on the Bombay Stock Exchange (BSE). The stock outperforms the general market price (GMP) trend, drawing investor attention. The company specializes in pharmaceutical formulations and active pharmaceutical ingredients (APIs).
Dec 2024business-standard.comNews article